Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
Single intravenous administration of TAH-1005 is performed in patients with differentiated
thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect
with standard treatment or who have difficulty in implementing and continuing standard
treatment. The safety, pharmacokinetics, absorbed dose, and efficacy will be evaluated to
determine the recommended dose for Phase II clinical trial.